145 related articles for article (PubMed ID: 32829780)
1. 6PGD Upregulation is Associated with Chemo- and Immuno-Resistance of Renal Cell Carcinoma via AMPK Signaling-Dependent NADPH-Mediated Metabolic Reprograming.
Cao J; Sun X; Zhang X; Chen D
Am J Med Sci; 2020 Sep; 360(3):279-286. PubMed ID: 32829780
[TBL] [Abstract][Full Text] [Related]
2. 6PGD inhibition sensitizes hepatocellular carcinoma to chemotherapy via AMPK activation and metabolic reprogramming.
Chen H; Wu D; Bao L; Yin T; Lei D; Yu J; Tong X
Biomed Pharmacother; 2019 Mar; 111():1353-1358. PubMed ID: 30841449
[TBL] [Abstract][Full Text] [Related]
3. Inhibiting 6-phosphogluconate dehydrogenase selectively targets breast cancer through AMPK activation.
Yang X; Peng X; Huang J
Clin Transl Oncol; 2018 Sep; 20(9):1145-1152. PubMed ID: 29340974
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting 6-phosphogluconate dehydrogenase enhances chemotherapy efficacy in cervical cancer via AMPK-independent inhibition of RhoA and Rac1.
Guo H; Xiang Z; Zhang Y; Sun D
Clin Transl Oncol; 2019 Apr; 21(4):404-411. PubMed ID: 30182212
[TBL] [Abstract][Full Text] [Related]
5. Inhibiting 6-phosphogluconate dehydrogenase reverses doxorubicin resistance in anaplastic thyroid cancer via inhibiting NADPH-dependent metabolic reprogramming.
Ma L; Cheng Q
Biochem Biophys Res Commun; 2018 Apr; 498(4):912-917. PubMed ID: 29534964
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of 6-Phosphogluconate Dehydrogenase Reverses Epirubicin Resistance Through Metabolic Reprograming in Triple-Negative Breast Cancer Cells.
Xu J; Ren G; Cheng Q
Technol Cancer Res Treat; 2023; 22():15330338231190737. PubMed ID: 37559469
[TBL] [Abstract][Full Text] [Related]
7. 6-Phosphogluconate dehydrogenase fuels multiple aspects of cancer cells: From cancer initiation to metastasis and chemoresistance.
Sarfraz I; Rasul A; Hussain G; Shah MA; Zahoor AF; Asrar M; Selamoglu Z; Ji XY; Adem Ş; Sarker SD
Biofactors; 2020 Jul; 46(4):550-562. PubMed ID: 32039535
[TBL] [Abstract][Full Text] [Related]
8. 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Lin R; Elf S; Shan C; Kang HB; Ji Q; Zhou L; Hitosugi T; Zhang L; Zhang S; Seo JH; Xie J; Tucker M; Gu TL; Sudderth J; Jiang L; Mitsche M; DeBerardinis RJ; Wu S; Li Y; Mao H; Chen PR; Wang D; Chen GZ; Hurwitz SJ; Lonial S; Arellano ML; Khoury HJ; Khuri FR; Lee BH; Lei Q; Brat DJ; Ye K; Boggon TJ; He C; Kang S; Fan J; Chen J
Nat Cell Biol; 2015 Nov; 17(11):1484-96. PubMed ID: 26479318
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of MAGEA6 Activates AMP-Activated Protein Kinase (AMPK) Signaling to Inhibit Human Renal Cell Carcinoma Cells.
Ye X; Xie J; Huang H; Deng Z
Cell Physiol Biochem; 2018; 45(3):1205-1218. PubMed ID: 29448247
[TBL] [Abstract][Full Text] [Related]
10. 6-Phosphogluconate dehydrogenase regulates tumor cell migration in vitro by regulating receptor tyrosine kinase c-Met.
Chan B; VanderLaan PA; Sukhatme VP
Biochem Biophys Res Commun; 2013 Sep; 439(2):247-51. PubMed ID: 23973484
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.
Cao J; Sun X; Zhang X; Chen D
Clin Transl Oncol; 2018 Jun; 20(6):761-767. PubMed ID: 29086249
[TBL] [Abstract][Full Text] [Related]
12. A feedback loop between the androgen receptor and 6-phosphogluoconate dehydrogenase (6PGD) drives prostate cancer growth.
Gillis JL; Hinneh JA; Ryan NK; Irani S; Moldovan M; Quek LE; Shrestha RK; Hanson AR; Xie J; Hoy AJ; Holst J; Centenera MM; Mills IG; Lynn DJ; Selth LA; Butler LM
Elife; 2021 Aug; 10():. PubMed ID: 34382934
[TBL] [Abstract][Full Text] [Related]
13. Tyrosine phosphorylation activates 6-phosphogluconate dehydrogenase and promotes tumor growth and radiation resistance.
Liu R; Li W; Tao B; Wang X; Yang Z; Zhang Y; Wang C; Liu R; Gao H; Liang J; Yang W
Nat Commun; 2019 Mar; 10(1):991. PubMed ID: 30824700
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-6 induces drug resistance in renal cell carcinoma.
Ishibashi K; Koguchi T; Matsuoka K; Onagi A; Tanji R; Takinami-Honda R; Hoshi S; Onoda M; Kurimura Y; Hata J; Sato Y; Kataoka M; Ogawsa S; Haga N; Kojima Y
Fukushima J Med Sci; 2018 Dec; 64(3):103-110. PubMed ID: 30369518
[TBL] [Abstract][Full Text] [Related]
15. AMPK as a therapeutic target in renal cell carcinoma.
Woodard J; Joshi S; Viollet B; Hay N; Platanias LC
Cancer Biol Ther; 2010 Dec; 10(11):1168-77. PubMed ID: 20948309
[TBL] [Abstract][Full Text] [Related]
16. Critical Role of 6-Phosphogluconate Dehydrogenase in TAp73-Mediated Cancer Cell Proliferation.
Qiao R; Wei M; Chen H; Zhang X; Zhang J; Gao L; Ma H; Wang Y; Li L
Mol Cancer Res; 2023 Aug; 21(8):825-835. PubMed ID: 37071129
[TBL] [Abstract][Full Text] [Related]
17. Nox4 mediates renal cell carcinoma cell invasion through hypoxia-induced interleukin 6- and 8- production.
Fitzgerald JP; Nayak B; Shanmugasundaram K; Friedrichs W; Sudarshan S; Eid AA; DeNapoli T; Parekh DJ; Gorin Y; Block K
PLoS One; 2012; 7(1):e30712. PubMed ID: 22303451
[TBL] [Abstract][Full Text] [Related]
18. Blockade of 6-phosphogluconate dehydrogenase generates CD8
Daneshmandi S; Cassel T; Lin P; Higashi RM; Wulf GM; Boussiotis VA; Fan TW; Seth P
Cell Rep; 2021 Mar; 34(10):108831. PubMed ID: 33691103
[TBL] [Abstract][Full Text] [Related]
19. Patient samples of renal cell carcinoma show reduced expression of TRAF1 compared with normal kidney and functional studies in vitro indicate TRAF1 promotes apoptosis: potential for targeted therapy.
Rajandram R; Bennett NC; Wang Z; Perry-Keene J; Vesey DA; Johnson DW; Gobe GC
Pathology; 2012 Aug; 44(5):453-9. PubMed ID: 22810054
[TBL] [Abstract][Full Text] [Related]
20. Evidence for a direct cross-talk between malic enzyme and the pentose phosphate pathway via structural interactions.
Yao P; Sun H; Xu C; Chen T; Zou B; Jiang P; Du W
J Biol Chem; 2017 Oct; 292(41):17113-17120. PubMed ID: 28848047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
